


Supplement C

European Survey for Lupus Patients 2019 (ESLP-2019)

This supplementary file gives an overview of the prescribed daily dose of HCQ (mg/kg/day) in Europe, based on the calculated ideal body weight and reported actual body weight.

Previously, a daily HCQ dose of ≤ 6.5 mg/kg ideal body weight (up to a maximum of 400 mg daily) was considered a safe cut-off associated with reduced risk of retinal toxicity [1-4]. In the ESLP-2019, a total of 1679 out of 1988 (84.5%) respondents have reported their body height and HCQ dose, allowing the calculation of the ideal body weight and subsequently the daily HCQ dose (mg/kg/day) based on ideal body weight (calculated for men: [(height (cm) – 152.4) \times 0.91 + 50], and for woman: [(height (cm) – 152.4) \times 0.91 + 45.5]). According to our data, 673 out of 1679 respondents (40.1%) are prescribed HCQ at a dose > 6.5 mg/kg/day ideal body weight.

Recently, the safety dose cut-off was changed to ≤ 5 mg/kg/day actual body weight [5-6]. A total of 1674 out of 1988 (84.2%) respondents using HCQ have reported both their actual body weight (kg) and HCQ dose (mg/day). Our data shows that 616 out of 1674 respondents (36.8%) are prescribed HCQ at a dose > 5.0 mg/kg/day actual body weight.



Supplemental references

- [1] Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. *Ophthalmology* 2002;109:1377–82.
- [2] Bertias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. *Ann Rheum Dis*. 2008;67(2):195–205.
- [3] Bourke BJ, Jones S, Rajammal AK, Silman A, Smith R. Hydroxychloroquine and ocular toxicity recommendations on screening. The Royal College of Ophthalmologists in association with The British Society for Rheumatology and the British Association of Dermatologists. 2009.
- [4] Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. *Ophthalmology*. 2011;118(2):415–422.
- [5] Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology*. 2016 Jun;123(6):1386-94.
- [6] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:736-745 doi: 10.1136/annrheumdis-2019-215089 [published Online First: 29 March 2019].